Lymphangiogenesis in colorectal cancer - Prognostic and therapeutic aspects

Eirik Sundlisæter*, Aly Dicko, Per Øystein Sakariassen, Karl Sondenaa, Per Øyvind Enger, Rolf Bjerkvig

*Corresponding author for this work

Research output: Contribution to journalShort surveypeer-review

43 Citations (Scopus)


Colorectal cancer (CRC) represents the second most common cause of cancer mortality in the western world. The tumors frequently show metastatic spread which affects different organs such as lymph nodes, liver and lungs. Although the pattern of spread may vary, the initial step usually involves dissemination to regional lymph nodes. At present it is clear that neovessel formation, including lymphangiogenesis, represents key events in tumor progression. However, to what extent lymphangiogenesis contributes in the progression of CRC is unclear. This work focuses on recent progress within the field of tumor lymphangiogenesis with special reference to CRC, and on novel therapeutic strategies for anti-lymphangiogenic therapies. Inhibition of metastatic spread may be achieved by restriction of lymphatic vessel growth by using targeted therapeutic strategies towards molecules involved in lymphangiogenic signalling. Such adjuvant therapeutic approaches in addition to existing therapeutic strategies may represent a favourable treatment for CRCs with higher than average risk of disease recurrence and progression.

Original languageEnglish
Pages (from-to)1401-1409
Number of pages9
JournalInternational Journal of Cancer
Issue number7
Publication statusPublished - 1 Oct 2007
Externally publishedYes


  • Colorectal cancer
  • Lymphangiogenesis
  • Therapy


Dive into the research topics of 'Lymphangiogenesis in colorectal cancer - Prognostic and therapeutic aspects'. Together they form a unique fingerprint.

Cite this